{
    "name": "aspirin/chlorpheniramine/dextromethorphan",
    "comment": "OTC",
    "other_names": [
        "Alka-Seltzer Plus Flu"
    ],
    "classes": [
        "Cough/Cold",
        "Non-narcotic Combos",
        "Analgesic/Antihistamine/Antitussive Combos"
    ],
    "source": "https://reference.medscape.com/drug/alka-seltzer-plus-flu-aspirin-chlorpheniramine-dextromethorphan-999389",
    "pregnancy": {
        "common": [
            "Pregnancy category: D; avoid aspirin during pregnancy, particularly in third trimester (risk of premature closure of ductus arteriosus)",
            "Lactation: excreted in breast milk; do not breast feed",
            "Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: excreted in breast milk; do not breast feed"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Liver damage",
                "Hypoprothrombinemia",
                "Vitamin K deficiency",
                "Bleeding disorders",
                "Asthma",
                "Due to association of aspirin with Reye syndrome, do not use in children (<16 years) with viral infections",
                "Narrow-angle glaucoma",
                "Symptomatic prostate hypertrophy",
                "Bladder-neck obstruction",
                "Stenosing peptic ulcer"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Aspirin may cause transient decrease in renal function and aggravate chronic kidney disease; avoid use in patients with severe anemia, with history of blood coagulation defects, or taking anticoagulants",
                "Dextromethorphan: do not take for persistent or chronic cough associated with smoking, asthma, or emphysema, or if it is accompanied by excessive phlegm unless directed by a healthcare provider; may slow respiration rate",
                "Chlorpheniramine: may cause significant confusional symptoms; not for administration to premature or full-term neonates"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib and aspirin both increase  anticoagulation. Contraindicated. Antiplatelet drugs, except for low-dose aspirin (=81 mg qDay), during the first 3 months of treatment are contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide increases levels of aspirin by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "aspirin, mifepristone. Other (see comment). Contraindicated. \nComment: Aspirin induced antiplatelet activity may induce excessive bleeding after an abortion w/mifepristone (RU 486)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benazepril",
            "description": {
                "common": "aspirin, benazepril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and chlorpheniramine both increase  sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium/magnesium/potassium/sodium oxybates",
            "description": {
                "common": "chlorpheniramine, calcium/magnesium/potassium/sodium oxybates.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caplacizumab",
            "description": {
                "common": "caplacizumab, aspirin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "captopril",
            "description": {
                "common": "aspirin, captopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "chlorpheniramine, eluxadoline.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enalapril",
            "description": {
                "common": "aspirin, enalapril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosinopril",
            "description": {
                "common": "aspirin, fosinopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "ibuprofen decreases effects of aspirin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Ibuprofen decreases the antiplatelet effects of low-dose aspirin by blocking the active site of platelet cyclooxygenase. Administer ibuprofen 8 h before aspirin or at least 2-4 h after aspirin. The effect of other NSAIDs on aspirin is not established."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "ibuprofen IV increases toxicity of aspirin by anticoagulation. Avoid or Use Alternate Drug. increases risk of bleeding."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid increases effects of chlorpheniramine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects.  MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketorolac",
            "description": {
                "common": "aspirin, ketorolac.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "aspirin, ketorolac intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lesinurad",
            "description": {
                "common": "aspirin decreases effects of lesinurad by unspecified interaction mechanism. Avoid or Use Alternate Drug. Aspirin at doses >325 mg/day may decrease lesinurad efficacy. Aspirin doses 325 mg/day or less (ie, for cardiovascular event prophylaxis) does not decrease lesinurad efficacy and can be coadministered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisinopril",
            "description": {
                "common": "aspirin, lisinopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "aspirin, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that directly affect the pituitary secretion of growth hormone (GH) may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "aspirin, measles, mumps, rubella and varicella vaccine, live. Mechanism: unspecified interaction mechanism. Avoid or Use Alternate Drug. Risk of Reye's Syndrome with combination; avoid salicylate use for 6 wks after vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methotrexate",
            "description": {
                "common": "aspirin increases levels of methotrexate by decreasing renal clearance. Avoid or Use Alternate Drug. Caution should be exercised when salicylates are given in combination with methotrexate.  Risk for drug interactions with methotrexate is greatest during high-dose methotrexate therapy, it has been recommended that any of these drugs be used cautiously with methotrexate even when methotrexate is used in low doses."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "chlorpheniramine, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "aspirin will decrease the level or effect of mifepristone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitotane",
            "description": {
                "common": "aspirin will decrease the level or effect of mitotane by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moexipril",
            "description": {
                "common": "aspirin, moexipril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "chlorpheniramine and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "aspirin increases levels of pemetrexed by unspecified interaction mechanism. Avoid or Use Alternate Drug. Interrupt dosing in all patients taking NSAIDs with long elimination half-lives for at least 5d before, the day of, and 2d following pemetrexed administration. If coadministration of an NSAID is necessary, closely monitor patients for toxicity, especially myelosuppression, renal toxicity, and GI toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perindopril",
            "description": {
                "common": "aspirin, perindopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "probenecid",
            "description": {
                "common": "aspirin decreases effects of probenecid by acidic (anionic) drug competition for renal tubular clearance. Avoid or Use Alternate Drug. Aspirin decreases uricosuric action of probenecid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinapril",
            "description": {
                "common": "aspirin, quinapril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ramipril",
            "description": {
                "common": "aspirin, ramipril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium oxybate",
            "description": {
                "common": "chlorpheniramine, sodium oxybate.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "aspirin increases effects of ticlopidine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trandolapril",
            "description": {
                "common": "aspirin, trandolapril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine increases effects of chlorpheniramine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects.  MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "aspirin, varicella virus vaccine live. Mechanism: unspecified interaction mechanism. Avoid or Use Alternate Drug. Risk of Reye's Syndrome with combination; avoid salicylate use for 6 wks after vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abciximab",
            "description": {
                "common": "aspirin, abciximab.\nEither increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib increases effects of aspirin by anticoagulation. Modify Therapy/Monitor Closely. Coadministration of acalabrutinib with antiplatelets or anticoagulants may further increase risk of hemorrhage. Monitor for signs of bleeding and consider the benefit-risk of withholding acalabrutinib for 3-7 days presurgery and postsurgery depending upon the type of surgery and the risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "aceclofenac and aspirin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "acemetacin and aspirin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide, aspirin.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "agrimony",
            "description": {
                "common": "aspirin and agrimony both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "chlorpheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfalfa",
            "description": {
                "common": "aspirin and alfalfa both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "chlorpheniramine and alfentanil both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "aspirin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aliskiren",
            "description": {
                "common": "aspirin will decrease the level or effect of aliskiren by  Other (see comment). Use Caution/Monitor. In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Monitor renal function periodically."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "chlorpheniramine and alprazolam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alteplase",
            "description": {
                "common": "aspirin, alteplase.\nEither increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "American ginseng",
            "description": {
                "common": "aspirin and American ginseng both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifampridine",
            "description": {
                "common": "chlorpheniramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "amiloride and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "chlorpheniramine and amitriptyline both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "chlorpheniramine and amobarbital both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "chlorpheniramine and amoxapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxicillin",
            "description": {
                "common": "amoxicillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ampicillin",
            "description": {
                "common": "ampicillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anagrelide",
            "description": {
                "common": "aspirin, anagrelide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; increases risk of bleeding; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apixaban",
            "description": {
                "common": "aspirin and apixaban both increase  anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (<100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if  treated concomitantly with low-dose aspiriin. Avoid coadministration with chronic use of higher dose aspirin. In 1 trial (APPRAISE-2), therapy was terminated because of significantly increased bleeding when apixaban was administered with dual antiplatelet therapy (eg, aspirin plus clopidogrel) compared with single antiplatelet treatment"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "chlorpheniramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "chlorpheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "chlorpheniramine and aripiprazole both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "chlorpheniramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azelastine",
            "description": {
                "common": "azelastine and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azficel-T",
            "description": {
                "common": "azficel-T, aspirin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking aspirin may experience increased bruising or bleeding at biopsy and/or injection sites. Concomitant use of aspirin is not recommended. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azilsartan",
            "description": {
                "common": "aspirin, azilsartan.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "baclofen",
            "description": {
                "common": "chlorpheniramine and baclofen both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "chlorpheniramine and belladonna and opium both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bemiparin",
            "description": {
                "common": "bemiparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "benazepril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "aspirin increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benperidol",
            "description": {
                "common": "chlorpheniramine and benperidol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzphetamine",
            "description": {
                "common": "chlorpheniramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "aspirin, betrixaban.\nEither increases levels of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bimatoprost",
            "description": {
                "common": "bimatoprost, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexanolone",
            "description": {
                "common": "brexanolone, chlorpheniramine.\nEither increases toxicity of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brinzolamide",
            "description": {
                "common": "brinzolamide, aspirin.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brompheniramine",
            "description": {
                "common": "brompheniramine and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bumetanide",
            "description": {
                "common": "aspirin increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "chlorpheniramine and buprenorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "chlorpheniramine and buprenorphine buccal both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "chlorpheniramine and butabarbital both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "chlorpheniramine and butalbital both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butorphanol",
            "description": {
                "common": "chlorpheniramine and butorphanol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "caffeine",
            "description": {
                "common": "chlorpheniramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "candesartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "captopril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high dose aspirin, elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbenoxolone",
            "description": {
                "common": "aspirin increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbinoxamine",
            "description": {
                "common": "carbinoxamine and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "chlorpheniramine and carisoprodol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "carvedilol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "aspirin and celecoxib both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloral hydrate",
            "description": {
                "common": "chlorpheniramine and chloral hydrate both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "chlorpheniramine and chlordiazepoxide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "aspirin increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpheniramine and chlorpromazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "aspirin increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "aspirin increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorzoxazone",
            "description": {
                "common": "chlorpheniramine and chlorzoxazone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "aspirin and choline magnesium trisalicylate both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cilostazol",
            "description": {
                "common": "aspirin, cilostazol.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnamon",
            "description": {
                "common": "aspirin and cinnamon both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnarizine",
            "description": {
                "common": "chlorpheniramine and cinnarizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "aspirin decreases levels of ciprofloxacin by Other (see comment). Use Caution/Monitor. \nComment: Buffered aspirin may decrease absorption of quinolones. Consider administering 2 hr before or 6 hr after, buffered aspirin administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clemastine",
            "description": {
                "common": "chlorpheniramine and clemastine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "chlorpheniramine, clobazam. Other (see comment). Use Caution/Monitor. \nComment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "chlorpheniramine and clonazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "aspirin, clopidogrel.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "chlorpheniramine and clorazepate both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "chlorpheniramine and clozapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "chlorpheniramine and codeine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "collagenase clostridium histolyticum",
            "description": {
                "common": "aspirin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cordyceps",
            "description": {
                "common": "aspirin and cordyceps both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "aspirin, cortisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of chlorpheniramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "chlorpheniramine and cyclizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "chlorpheniramine and cyclobenzaprine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "aspirin increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "chlorpheniramine and cyproheptadine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "dabigatran and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (<100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if treated concomitantly with low-dose aspirin. Avoid coadministration with chronic use of higher dose aspirin"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dantrolene",
            "description": {
                "common": "chlorpheniramine and dantrolene both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "chlorpheniramine and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox, aspirin. Other (see comment). Use Caution/Monitor. \nComment:  Combination may increase GI bleeding, ulceration and irritation. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "defibrotide",
            "description": {
                "common": "defibrotide increases effects of aspirin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Defibrotide may enhance effects of platelet inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "aspirin, deflazacort.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "chlorpheniramine and desipramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desirudin",
            "description": {
                "common": "aspirin, desirudin.\nEither increases levels of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "chlorpheniramine and deutetrabenazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "aspirin, dexamethasone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexchlorpheniramine",
            "description": {
                "common": "chlorpheniramine and dexchlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "chlorpheniramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "chlorpheniramine and dexmedetomidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "chlorpheniramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "chlorpheniramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromoramide",
            "description": {
                "common": "chlorpheniramine and dextromoramide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diamorphine",
            "description": {
                "common": "chlorpheniramine and diamorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "chlorpheniramine and diazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "diazepam intranasal, chlorpheniramine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "aspirin and diclofenac both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicloxacillin",
            "description": {
                "common": "dicloxacillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diethylpropion",
            "description": {
                "common": "chlorpheniramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "chlorpheniramine and difenoxin hcl both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "aspirin and diflunisal both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "aspirin and digoxin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "chlorpheniramine and dimenhydrinate both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "chlorpheniramine and diphenhydramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "chlorpheniramine and diphenoxylate hcl both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dipipanone",
            "description": {
                "common": "chlorpheniramine and dipipanone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "aspirin, dipyridamole.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "chlorpheniramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil transdermal",
            "description": {
                "common": "donepezil transdermal, chlorpheniramine.\nEither decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dong quai",
            "description": {
                "common": "aspirin and dong quai both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopamine",
            "description": {
                "common": "chlorpheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopexamine",
            "description": {
                "common": "aspirin increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dosulepin",
            "description": {
                "common": "chlorpheniramine and dosulepin both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxazosin",
            "description": {
                "common": "aspirin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "chlorpheniramine and doxepin both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxylamine",
            "description": {
                "common": "chlorpheniramine and doxylamine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "chlorpheniramine and droperidol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "drospirenone and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "edoxaban",
            "description": {
                "common": "edoxaban, aspirin.\nEither increases toxicity of the other by anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (<100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if treated concomitantly with low-dose aspirin. Avoid coadministration with chronic use of higher dose aspirin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF, aspirin.\nEither increases toxicity of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "enalapril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment:  May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "chlorpheniramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin and aspirin both increase  anticoagulation. Use Caution/Monitor. Additive effects are intended when both drugs are prescribed as indicated for unstable angina, non-Q-wave MI, and STEMI"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "aspirin increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "aspirin increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "chlorpheniramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "aspirin and epoprostenol both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, chlorpheniramine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "eprosartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eptifibatide",
            "description": {
                "common": "aspirin, eptifibatide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estazolam",
            "description": {
                "common": "chlorpheniramine and estazolam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "aspirin increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "chlorpheniramine and ethanol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "aspirin and etodolac both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etomidate",
            "description": {
                "common": "etomidate and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenbufen",
            "description": {
                "common": "aspirin and fenbufen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "chlorpheniramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fennel",
            "description": {
                "common": "aspirin and fennel both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "aspirin and fenoprofen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "fentanyl, chlorpheniramine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "fentanyl intranasal, chlorpheniramine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "fentanyl transdermal, chlorpheniramine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "fentanyl transmucosal, chlorpheniramine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "feverfew",
            "description": {
                "common": "aspirin and feverfew both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil",
            "description": {
                "common": "fish oil, aspirin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking fish oil and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil triglycerides",
            "description": {
                "common": "fish oil triglycerides will increase the level or effect of aspirin by  anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "chlorpheniramine and flibanserin both increase  sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "aspirin, fludrocortisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "chlorpheniramine and fluphenazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurazepam",
            "description": {
                "common": "chlorpheniramine and flurazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "aspirin and flurbiprofen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "fondaparinux and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "chlorpheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "forskolin",
            "description": {
                "common": "aspirin and forskolin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosinopril",
            "description": {
                "common": "fosinopril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment:  May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "furosemide",
            "description": {
                "common": "aspirin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin, chlorpheniramine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil, chlorpheniramine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "chlorpheniramine and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "garlic",
            "description": {
                "common": "aspirin and garlic both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "aspirin increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginger",
            "description": {
                "common": "aspirin and ginger both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginkgo biloba",
            "description": {
                "common": "aspirin and ginkgo biloba both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "aspirin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "aspirin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "aspirin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrronium tosylate topical",
            "description": {
                "common": "glycopyrronium tosylate topical, chlorpheniramine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gotu kola",
            "description": {
                "common": "gotu kola increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea increases effects of aspirin by pharmacodynamic synergism. Use Caution/Monitor. (Theoretical, due to caffeine content).   Combination may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "griseofulvin decreases levels of aspirin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "chlorpheniramine and haloperidol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hawthorn",
            "description": {
                "common": "hawthorn increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hops",
            "description": {
                "common": "hops increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "horse chestnut seed",
            "description": {
                "common": "aspirin and horse chestnut seed both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyaluronidase",
            "description": {
                "common": "chlorpheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydralazine",
            "description": {
                "common": "aspirin decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "chlorpheniramine and hydromorphone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "aspirin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "aspirin, hydrocortisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "chlorpheniramine and hydroxyzine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib will increase the level or effect of aspirin by  anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "aspirin and ibuprofen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "aspirin will increase the level or effect of ibuprofen IV by  acidic (anionic) drug competition for renal tubular clearance. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "icosapent",
            "description": {
                "common": "icosapent, aspirin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "chlorpheniramine and iloperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib, aspirin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is   coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "chlorpheniramine and imipramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "aspirin increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "aspirin and indomethacin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "aspirin increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "aspirin increases effects of insulin aspart protamine/insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "aspirin increases effects of insulin degludec by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "aspirin, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "aspirin increases effects of insulin detemir by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "aspirin increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "aspirin increases effects of insulin glulisine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "aspirin increases effects of insulin inhaled by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "aspirin increases effects of insulin isophane human/insulin regular human by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "aspirin increases effects of insulin lispro by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "aspirin increases effects of insulin lispro protamine/insulin lispro by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "aspirin increases effects of insulin NPH by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "aspirin increases effects of insulin regular human by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "irbesartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "chlorpheniramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "aspirin and ketoprofen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "kava",
            "description": {
                "common": "kava increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "ketamine and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "aspirin and ketorolac both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "aspirin and ketorolac intranasal both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketotifen, ophthalmic",
            "description": {
                "common": "chlorpheniramine and ketotifen, ophthalmic both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "labetalol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, chlorpheniramine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "latanoprost",
            "description": {
                "common": "latanoprost, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "latanoprostene bunod ophthalmic",
            "description": {
                "common": "latanoprostene bunod ophthalmic, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant, chlorpheniramine.\nEither increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of chlorpheniramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "aspirin increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "levomilnacipran, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levorphanol",
            "description": {
                "common": "chlorpheniramine and levorphanol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "chlorpheniramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisinopril",
            "description": {
                "common": "lisinopril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "aspirin increases levels of lithium by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "chlorpheniramine and lofepramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofexidine",
            "description": {
                "common": "chlorpheniramine and lofexidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loprazolam",
            "description": {
                "common": "chlorpheniramine and loprazolam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "chlorpheniramine and lorazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lormetazepam",
            "description": {
                "common": "chlorpheniramine and lormetazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "aspirin and lornoxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "losartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "chlorpheniramine and loxapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "chlorpheniramine and loxapine inhaled both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, chlorpheniramine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "chlorpheniramine and maprotiline both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "chlorpheniramine and marijuana both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "aspirin and meclofenamate both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "aspirin and mefenamic acid both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melatonin",
            "description": {
                "common": "melatonin increases effects of aspirin by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "aspirin and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "chlorpheniramine and meperidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meprobamate",
            "description": {
                "common": "chlorpheniramine and meprobamate both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mesalamine",
            "description": {
                "common": "mesalamine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaproterenol",
            "description": {
                "common": "aspirin increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "chlorpheniramine and metaxalone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methazolamide",
            "description": {
                "common": "methazolamide, aspirin.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "chlorpheniramine and methadone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "chlorpheniramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methocarbamol",
            "description": {
                "common": "chlorpheniramine and methocarbamol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "aspirin increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylenedioxymethamphetamine",
            "description": {
                "common": "chlorpheniramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "aspirin, methylprednisolone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "aspirin increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "chlorpheniramine and midazolam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, chlorpheniramine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midodrine",
            "description": {
                "common": "chlorpheniramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "chlorpheniramine and mirtazapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mistletoe",
            "description": {
                "common": "aspirin increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of chlorpheniramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "modafinil",
            "description": {
                "common": "chlorpheniramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moexipril",
            "description": {
                "common": "moexipril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "chlorpheniramine and morphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "motherwort",
            "description": {
                "common": "chlorpheniramine and motherwort both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "aspirin decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxonidine",
            "description": {
                "common": "chlorpheniramine and moxonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "aspirin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabilone",
            "description": {
                "common": "chlorpheniramine and nabilone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "aspirin and nabumetone both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "chlorpheniramine and nalbuphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "aspirin and naproxen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nettle",
            "description": {
                "common": "aspirin increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitazoxanide",
            "description": {
                "common": "nitazoxanide, aspirin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "aspirin will increase the level or effect of nitroglycerin rectal by  Other (see comment). Use Caution/Monitor. The pharmacological effects of nitroglycerin may be enhanced by concomitant administration of aspirin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin sublingual",
            "description": {
                "common": "aspirin increases effects of nitroglycerin sublingual by additive vasodilation. Use Caution/Monitor. Vasodilatory and hemodynamic effects of NTG may be enhanced by coadministration with aspirin (additive effect desirable for emergent treatment)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "aspirin increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "chlorpheniramine and nortriptyline both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "olmesartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "chlorpheniramine and olanzapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omega 3 carboxylic acids",
            "description": {
                "common": "omega 3 carboxylic acids, aspirin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3 acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omega 3 fatty acids",
            "description": {
                "common": "omega 3 fatty acids, aspirin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "opium tincture",
            "description": {
                "common": "chlorpheniramine and opium tincture both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "chlorpheniramine and orphenadrine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "aspirin, ospemifene.\nEither increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxacillin",
            "description": {
                "common": "oxacillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "aspirin and oxaprozin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxazepam",
            "description": {
                "common": "chlorpheniramine and oxazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "chlorpheniramine and oxycodone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "chlorpheniramine and oxymorphone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "chlorpheniramine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "panax ginseng",
            "description": {
                "common": "aspirin and panax ginseng both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "papaveretum",
            "description": {
                "common": "chlorpheniramine and papaveretum both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "papaverine",
            "description": {
                "common": "chlorpheniramine and papaverine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "aspirin and parecoxib both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "passion flower",
            "description": {
                "common": "passion flower increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pau d'arco",
            "description": {
                "common": "aspirin and pau d'arco both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegaspargase",
            "description": {
                "common": "pegaspargase increases effects of aspirin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillin G aqueous",
            "description": {
                "common": "penicillin G aqueous, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentazocine",
            "description": {
                "common": "chlorpheniramine and pentazocine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "chlorpheniramine and pentobarbital both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perindopril",
            "description": {
                "common": "perindopril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high doses of aspirin,in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "chlorpheniramine and perphenazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phendimetrazine",
            "description": {
                "common": "chlorpheniramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine increases effects of chlorpheniramine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenindione",
            "description": {
                "common": "phenindione and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "chlorpheniramine and phenobarbital both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "aspirin decreases effects of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentermine",
            "description": {
                "common": "chlorpheniramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentolamine",
            "description": {
                "common": "aspirin decreases effects of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine",
            "description": {
                "common": "chlorpheniramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "chlorpheniramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pholcodine",
            "description": {
                "common": "chlorpheniramine and pholcodine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phytoestrogens",
            "description": {
                "common": "aspirin and phytoestrogens both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "chlorpheniramine and pimozide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pirbuterol",
            "description": {
                "common": "aspirin increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "aspirin and piroxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "pregabalin, chlorpheniramine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pivmecillinam",
            "description": {
                "common": "pivmecillinam, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "aspirin and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "aspirin and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "aspirin and potassium citrate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "aspirin, prasugrel.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "aspirin decreases effects of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "aspirin, prednisolone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "aspirin, prednisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "chlorpheniramine and primidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "chlorpheniramine and prochlorperazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "chlorpheniramine and promethazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propylhexedrine",
            "description": {
                "common": "chlorpheniramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protamine",
            "description": {
                "common": "protamine and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "chlorpheniramine and protriptyline both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quazepam",
            "description": {
                "common": "chlorpheniramine and quazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "chlorpheniramine and quetiapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinapril",
            "description": {
                "common": "quinapril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high doses of aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramelteon",
            "description": {
                "common": "chlorpheniramine and ramelteon both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramipril",
            "description": {
                "common": "ramipril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high doses of aspirin, in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reishi",
            "description": {
                "common": "aspirin and reishi both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reteplase",
            "description": {
                "common": "aspirin, reteplase.\nEither increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "chlorpheniramine and risperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "aspirin, rivaroxaban.\nEither increases toxicity of the other by anticoagulation. Use Caution/Monitor. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (<100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if treated concomitantly with low-dose aspirin. Avoid coadministration with chronic use of higher dose aspirin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivastigmine",
            "description": {
                "common": "rivastigmine increases toxicity of aspirin by pharmacodynamic synergism. Use Caution/Monitor. Monitor patients for symptoms of active or occult gastrointestinal bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "sacubitril/valsartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "aspirin and salicylates (non-asa) both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salmeterol",
            "description": {
                "common": "chlorpheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "aspirin and salsalate both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scullcap",
            "description": {
                "common": "chlorpheniramine and scullcap both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saw palmetto",
            "description": {
                "common": "saw palmetto increases toxicity of aspirin by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "chlorpheniramine and secobarbital both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selumetinib",
            "description": {
                "common": "aspirin and selumetinib both increase  anticoagulation. Modify Therapy/Monitor Closely. An increased risk of bleeding may occur in patients taking a vitamin-K antagonist or an antiplatelet agent with selumetinib. Monitor for bleeding and INR or PT in patients coadministered a vitamin-K antagonist or an antiplatelet agent with selumetinib."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Siberian ginseng",
            "description": {
                "common": "aspirin and Siberian ginseng both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane and chlorpheniramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "chlorpheniramine and shepherd's purse both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "silodosin",
            "description": {
                "common": "aspirin decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "aspirin, sodium picosulfate/magnesium oxide/anhydrous citric acid.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May be associated with fluid and electrolyte imbalances."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of aspirin by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of aspirin by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sparsentan",
            "description": {
                "common": "aspirin and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "spironolactone and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, chlorpheniramine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "aspirin and succinylcholine both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil",
            "description": {
                "common": "chlorpheniramine and sufentanil both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "aspirin, sulfamethoxazole.\nEither increases effects of the other by plasma protein binding competition. Use Caution/Monitor. Due to high protein binding capacity of both drugs, one may displace the other when coadministered leading to an enhanced effect of the displaced drug; risk is low with low dose aspirin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "aspirin and sulfasalazine both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "aspirin and sulindac both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafluprost",
            "description": {
                "common": "tafluprost, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "chlorpheniramine and tapentadol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temazepam",
            "description": {
                "common": "chlorpheniramine and temazepam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temocillin",
            "description": {
                "common": "temocillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "aspirin, tenecteplase.\nEither increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terazosin",
            "description": {
                "common": "aspirin decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbutaline",
            "description": {
                "common": "chlorpheniramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "chlorpheniramine and thioridazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "aspirin, ticagrelor. Other (see comment). Use Caution/Monitor. \nComment: Maintenance doses of aspirin above 100 mg decreases effectiveness of ticagrelor. Therefore, after the initial loading dose of aspirin (usually 325 mg), use ticagrelor with a maintenance dose of aspirin of 75-100 mg."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "chlorpheniramine and thiothixene both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticarcillin",
            "description": {
                "common": "ticarcillin, aspirin.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tirofiban",
            "description": {
                "common": "aspirin, tirofiban.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and aspirin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "aspirin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "aspirin increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "aspirin and tolfenamic acid both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "aspirin and tolmetin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "aspirin and tolvaptan both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "chlorpheniramine and topiramate both increase  sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "aspirin increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "chlorpheniramine and tramadol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trandolapril",
            "description": {
                "common": "trandolapril, aspirin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly with high dose aspirin, in elderly and volume depleted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "travoprost ophthalmic",
            "description": {
                "common": "travoprost ophthalmic, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "chlorpheniramine and trazodone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "aspirin, triamcinolone acetonide injectable suspension.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Aspirin in conjunction with corticosteroids in hypoprothrombinemia should used with caution. Clearance of salicylates may increase with concurrent use of corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "chlorpheniramine and triazolam both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamterene",
            "description": {
                "common": "triamterene and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclofos",
            "description": {
                "common": "chlorpheniramine and triclofos both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "chlorpheniramine and trifluoperazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "chlorpheniramine and trimipramine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triprolidine",
            "description": {
                "common": "chlorpheniramine and triprolidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valerian",
            "description": {
                "common": "valerian increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "aspirin increases levels of valproic acid by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "valsartan and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, aspirin.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "aspirin, vorapaxar.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "aspirin, vortioxetine.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Risk minimal with low-dose aspirin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "aspirin increases effects of warfarin by anticoagulation. Modify Therapy/Monitor Closely. Avoid coadministration of chronic high-dose aspirin. Aspirin's antiplatelet properties may increase anticoagulation effect of warfarin. The need for simultaneous use of low-dose aspirin and warfarin is common for patients with cardiovascular disease. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xylometazoline",
            "description": {
                "common": "chlorpheniramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "yohimbine",
            "description": {
                "common": "chlorpheniramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "aspirin, zanubrutinib.\nEither increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziconotide",
            "description": {
                "common": "chlorpheniramine and ziconotide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "chlorpheniramine and ziprasidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "aspirin decreases effects of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "aceclofenac will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acemetacin",
            "description": {
                "common": "acemetacin will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acyclovir",
            "description": {
                "common": "aspirin will increase the level or effect of acyclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alendronate",
            "description": {
                "common": "aspirin, alendronate.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide, aspirin. Mechanism: passive renal tubular reabsorption due to increased pH. Minor/Significance Unknown. Salicylate levels increased at moderate doses; salicylate levels decreased at large doses (d/t increased renal excretion of unchanged salicylic acid)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amikacin",
            "description": {
                "common": "aspirin increases levels of amikacin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aminohippurate sodium",
            "description": {
                "common": "aspirin will increase the level or effect of aminohippurate sodium by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anamu",
            "description": {
                "common": "aspirin and anamu both increase  anticoagulation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "aspirin will decrease the level or effect of anastrozole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ascorbic acid",
            "description": {
                "common": "ascorbic acid will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ashwagandha",
            "description": {
                "common": "ashwagandha increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "balsalazide",
            "description": {
                "common": "aspirin will increase the level or effect of balsalazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bismuth subsalicylate",
            "description": {
                "common": "bismuth subsalicylate increases effects of aspirin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "aspirin, bumetanide. Other (see comment). Minor/Significance Unknown. \nComment: Salicylates are less likely than other NSAIDs to interact w/bumetanide."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate, aspirin. Mechanism: passive renal tubular reabsorption due to increased pH. Minor/Significance Unknown. Salicylate levels increased at moderate doses; salicylate levels decreased at large doses (d/t increased renal excretion of unchanged salicylic acid)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefadroxil",
            "description": {
                "common": "cefadroxil will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefepime",
            "description": {
                "common": "cefepime will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefixime",
            "description": {
                "common": "cefixime will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefpirome",
            "description": {
                "common": "cefpirome will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefprozil",
            "description": {
                "common": "cefprozil will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftazidime",
            "description": {
                "common": "ceftazidime will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftibuten",
            "description": {
                "common": "ceftibuten will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celecoxib",
            "description": {
                "common": "aspirin will increase the level or effect of celecoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cephalexin",
            "description": {
                "common": "cephalexin will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceritinib",
            "description": {
                "common": "aspirin will decrease the level or effect of ceritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "aspirin will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "aspirin will increase the level or effect of choline magnesium trisalicylate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chromium",
            "description": {
                "common": "aspirin increases levels of chromium by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "creatine",
            "description": {
                "common": "creatine, aspirin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyanocobalamin",
            "description": {
                "common": "aspirin decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "danshen",
            "description": {
                "common": "aspirin and danshen both increase  anticoagulation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eucalyptus",
            "description": {
                "common": "chlorpheniramine and eucalyptus both increase  sedation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "devil's claw",
            "description": {
                "common": "aspirin and devil's claw both increase  anticoagulation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diclofenac",
            "description": {
                "common": "aspirin will increase the level or effect of diclofenac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diclofenac topical",
            "description": {
                "common": "diclofenac topical, aspirin.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Although low, there is systemic exposure to diclofenac topical; theoretically, concomitant administration with systemic NSAIDS or aspirin may result in increased NSAID adverse effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diflunisal",
            "description": {
                "common": "aspirin will increase the level or effect of diflunisal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem increases effects of aspirin by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "aspirin decreases effects of eplerenone by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol increases toxicity of aspirin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI bleeding."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etodolac",
            "description": {
                "common": "aspirin will increase the level or effect of etodolac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenbufen",
            "description": {
                "common": "aspirin will increase the level or effect of fenbufen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "aspirin will increase the level or effect of fenoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "feverfew",
            "description": {
                "common": "aspirin decreases effects of feverfew by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "aspirin will increase the level or effect of flurbiprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "folic acid",
            "description": {
                "common": "aspirin decreases levels of folic acid by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "aspirin decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "aspirin will increase the level or effect of ganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gentamicin",
            "description": {
                "common": "aspirin increases levels of gentamicin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "aspirin increases effects of glimepiride by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "aspirin increases effects of glipizide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "aspirin increases effects of glyburide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "aspirin will increase the level or effect of ibuprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imidapril",
            "description": {
                "common": "aspirin decreases effects of imidapril by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indomethacin",
            "description": {
                "common": "aspirin will increase the level or effect of indomethacin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "aspirin will increase the level or effect of ketoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketorolac",
            "description": {
                "common": "aspirin will increase the level or effect of ketorolac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "aspirin will increase the level or effect of ketorolac intranasal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "L-methylfolate",
            "description": {
                "common": "aspirin decreases levels of L-methylfolate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "aspirin will decrease the level or effect of larotrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "aspirin will increase the level or effect of lornoxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nettle",
            "description": {
                "common": "nettle increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "aspirin will increase the level or effect of meclofenamate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "aspirin will increase the level or effect of mefenamic acid by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meloxicam",
            "description": {
                "common": "aspirin will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mesalamine",
            "description": {
                "common": "aspirin will increase the level or effect of mesalamine by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nabumetone",
            "description": {
                "common": "aspirin will increase the level or effect of nabumetone by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "naproxen",
            "description": {
                "common": "aspirin will increase the level or effect of naproxen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "aspirin increases levels of neomycin PO by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "noni juice",
            "description": {
                "common": "aspirin and noni juice both increase  serum potassium. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin, aspirin. Other (see comment). Minor/Significance Unknown. \nComment: Risk of CNS stimulation/seizure.  Mechanism: Displacement of GABA from receptors in brain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "aspirin will increase the level or effect of oxaprozin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "parecoxib",
            "description": {
                "common": "aspirin will increase the level or effect of parecoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paromomycin",
            "description": {
                "common": "aspirin increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penicillin VK",
            "description": {
                "common": "penicillin VK, aspirin.\nEither increases levels of the other by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentazocine",
            "description": {
                "common": "aspirin, pentazocine.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Possible risk of renal papillary necrosis w/chronic Tx."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "piperacillin",
            "description": {
                "common": "piperacillin, aspirin.\nEither increases effects of the other by receptor binding competition. Minor/Significance Unknown. Salicylic acid could be displaced from protein binding sites or it could itself displace other protein-bound drugs and result in an enhanced effect of the displaced drug."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "piroxicam",
            "description": {
                "common": "aspirin will increase the level or effect of piroxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "rose hips will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sage",
            "description": {
                "common": "chlorpheniramine and sage both increase  sedation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "Siberian ginseng",
            "description": {
                "common": "Siberian ginseng increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "aspirin will increase the level or effect of salicylates (non-asa) by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Cerebral edema",
            "percent": null
        },
        {
            "name": "Coma",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Dysrhythmias",
            "percent": null
        },
        {
            "name": "Euphoria",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "GI bleeding",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        },
        {
            "name": "Hives",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "May potentiate peptic ulcer and cause stomach distress or heartburn",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Palpitations",
            "percent": null
        },
        {
            "name": "Prolonged prothrombin time",
            "percent": null
        },
        {
            "name": "Rashes",
            "percent": null
        },
        {
            "name": "Sedation",
            "percent": null
        },
        {
            "name": "Subdural or intracranial hemorrhage",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Thickening of bronchial secretions",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Tremors",
            "percent": null
        },
        {
            "name": "Ulceration and perforation",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Wheezing",
            "percent": null
        }
    ]
}